Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing
Decoy Therapeutics announced a PIPE financing of up to $21 million with a single healthcare-focused institutional investor to fund the advancement of its lead antiviral asset into clinical trials. The transaction includes $3.5 million in upfront gross proceeds at $5.91 per share, with milestone-based warrants potentially unlocking an additional $17.5 million tied to Phase 1 and Phase 2a trial progress in the EEA and UK.
Key figures
- Deal Value Usd
- 21000000
- Offering Price
- 5.91
- Phase 2a trial
- planned
- Phase of trial
- Phase 1
- Upfront proceeds usd
- 3500000
- Series a warrant potential usd
- 3500000
- Series b warrant potential usd
- 7000000
- Series c warrant potential usd
- 7000000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.